Liposome Drug Delivery Market (Liposome Structure: Unilamellar Liposomes, Multilamellar Liposomes, and Others; Product: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, and Others) - Global Industry Analysis, Size, Share, Growth, Tre

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,795	180 Pages	Transparency Market Research Pvt. Ltd.	August, 2023	TNPR18249886

Best Price Guarantee
Price	from $5,795
Length	180 Pages
Publisher	Transparency Market Research Pvt. Ltd.
Published Date	August, 2023
SKU	TNPR18249886

Liposome Drug Delivery Market (Liposome Structure: Unilamellar Liposomes, Multilamellar Liposomes, and Others; Product: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Liposome Drug Delivery Market – Scope of Report

TMR’s report on the global liposome drug delivery market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global liposome drug delivery market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global liposome drug delivery market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the liposome drug delivery market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global liposome drug delivery market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global liposome drug delivery market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global liposome drug delivery market.

The report delves into the competitive landscape of the global liposome drug delivery market. Key players operating in the global liposome drug delivery market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global liposome drug delivery market profiled in this report.

Key Questions Answered in Global Liposome Drug Delivery Market Report

What is the sales/revenue generated by liposome drug delivery across all regions during the forecast period?
What are the opportunities in the global liposome drug delivery market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Liposome Drug Delivery Market – Research Objectives and Research Approach

The comprehensive report on the global liposome drug delivery market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global liposome drug delivery market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global liposome drug delivery market.

1. Preface: 1.1. Market Definition and Scope; 1.2. Market Segmentation; 1.3. Key Research Objectives; 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Liposome Drug Delivery Market
4. Market Overview: 4.1. Introduction; 4.1.1. Segment Definition; 4.2. Overview; 4.3. Market Dynamics; 4.3.1. Drivers; 4.3.2. Restraints; 4.3.3. Opportunities; 4.4. Global Liposome Drug Delivery Market Analysis and Forecast, 2017-2031; 4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights: 5.1. Technological Advancements; 5.2. Overview: Liposome Drug delivery Systems; 5.3. Regulatory Scenario; 5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Liposome Drug Delivery Market Analysis and Forecast, by Liposome Structure: 6.1. Introduction & Definition; 6.2. Key Findings / Developments; 6.3. Market Value Forecast, by Liposome Structure, 2017-2031; 6.3.1. Unilamellar Liposomes; 6.3.1.1. Small; 6.3.1.2. Large; 6.3.2. Multilamellar liposomes; 6.3.3. Others; 6.4. Market Attractiveness Analysis, by Liposome Structure
7. Global Liposome Drug Delivery Market Analysis and Forecast, by Product: 7.1. Introduction & Definition; 7.2. Key Findings / Developments; 7.3. Market Value Forecast, by Product, 2017-2031; 7.3.1. Liposomal Doxorubicin; 7.3.2. Liposomal Paclitaxel; 7.3.3. Liposomal Amphotericin B; 7.3.4. Others; 7.4. Market Attractiveness Analysis, by Product
8. Global Liposome Drug Delivery Market Analysis and Forecast, by Technology: 8.1. Introduction & Definition; 8.2. Key Findings / Developments; 8.3. Market Value Forecast, by Technology, 2017-2031; 8.3.1. Stealth Liposome Technology; 8.3.2. Non PEGylated Liposome Technology; 8.3.3. DepoFoam Liposome Technology; 8.3.4. Lysolipid Thermally Sensitive Liposome Technology; 8.4. Market Attractiveness Analysis, by Technology
9. Global Liposome Drug Delivery Market Analysis and Forecast, by Application: 9.1. Introduction & Definition; 9.2. Key Findings / Developments; 9.3. Market Value Forecast, by Application, 2017-2031; 9.3.1. Fungal Diseases; 9.3.2. Cancer Therapy; 9.3.3. Pain Management; 9.3.4. Viral Vaccines; 9.3.5. Photodynamic Therapy; 9.3.6. Others; 9.4. Market Attractiveness Analysis, by Application
10. Global Liposome Drug Delivery Market Analysis and Forecast, by End-user: 10.1. Introduction & Definition; 10.2. Key Findings / Developments; 10.3. Market Value Forecast, by End-user, 2017-2031; 10.3.1. Hospitals; 10.3.2. Specialty Centers; 10.3.3. Ambulatory Surgical Centers; 10.3.4. Others; 10.4. Market Attractiveness Analysis, by End-user
11. Global Liposome Drug Delivery Market Analysis and Forecast, by Region: 11.1. Key Findings; 11.2. Market Value Forecast, by Region; 11.2.1. North America; 11.2.2. Europe; 11.2.3. Asia Pacific; 11.2.4. Latin America; 11.2.5. Middle East & Africa; 11.3. Market Attractiveness Analysis, by Region
12. North America Liposome Drug Delivery Market Analysis and Forecast: 12.1. Introduction; 12.1.1. Key Findings; 12.2. Market Value Forecast, by Liposome Structure, 2017-2031; 12.2.1. Unilamellar Liposomes; 12.2.1.1. Small; 12.2.1.2. Large; 12.2.2. Multilamellar liposomes; 12.2.3. Others; 12.3. Market Value Forecast, by Product, 2017-2031; 12.3.1. Liposomal Doxorubicin; 12.3.2. Liposomal Paclitaxel; 12.3.3. Liposomal Amphotericin B; 12.3.4. Others; 12.4. Market Value Forecast, by Technology, 2017-2031; 12.4.1. Stealth Liposome Technology; 12.4.2. Non PEGylated Liposome Technology; 12.4.3. DepoFoam Liposome Technology; 12.4.4. Lysolipid Thermally Sensitive Liposome Technology; 12.5. Market Value Forecast, by Application, 2017-2031; 12.5.1. Fungal Diseases; 12.5.2. Cancer Therapy; 12.5.3. Pain Management; 12.5.4. Viral Vaccines; 12.5.5. Photodynamic Therapy; 12.5.6. Others; 12.6. Market Value Forecast, by End-user, 2017-2031; 12.6.1. Hospitals; 12.6.2. Specialty Centers; 12.6.3. Ambulatory Surgical Centers; 12.6.4. Others; 12.7. Market Value Forecast, by Country, 2017-2031; 12.7.1. U.S.; 12.7.2. Canada; 12.8. Market Attractiveness Analysis; 12.8.1. By Liposome Structure; 12.8.2. By Product; 12.8.3. By Technology; 12.8.4. By Application; 12.8.5. By End-user; 12.8.6. By Country
13. Europe Liposome Drug Delivery Market Analysis and Forecast: 13.1. Introduction; 13.1.1. Key Findings; 13.2. Market Value Forecast, by Liposome Structure, 2017-2031; 13.2.1. Unilamellar Liposomes; 13.2.1.1. Small; 13.2.1.2. Large; 13.2.2. Multilamellar liposomes; 13.2.3. Others; 13.3. Market Value Forecast, by Product, 2017-2031; 13.3.1. Liposomal Doxorubicin; 13.3.2. Liposomal Paclitaxel; 13.3.3. Liposomal Amphotericin B; 13.3.4. Others; 13.4. Market Value Forecast, by Technology, 2017-2031; 13.4.1. Stealth Liposome Technology; 13.4.2. Non PEGylated Liposome Technology; 13.4.3. DepoFoam Liposome Technology; 13.4.4. Lysolipid Thermally Sensitive Liposome Technology; 13.5. Market Value Forecast, by Application, 2017-2031; 13.5.1. Fungal Diseases; 13.5.2. Cancer Therapy; 13.5.3. Pain Management; 13.5.4. Viral Vaccines; 13.5.5. Photodynamic Therapy; 13.5.6. Others; 13.6. Market Value Forecast, by End-user, 2017-2031; 13.6.1. Hospitals; 13.6.2. Specialty Centers; 13.6.3. Ambulatory Surgical Centers; 13.6.4. Others; 13.7. Market Value Forecast, by Country/Sub-region, 2017-2031; 13.7.1. Germany; 13.7.2. U.K; 13.7.3. France; 13.7.4. Italy; 13.7.5. Spain; 13.7.6. Rest of Europe; 13.8. Market Attractiveness Analysis; 13.8.1. By Liposome Structure; 13.8.2. By Product; 13.8.3. By Technology; 13.8.4. By Application; 13.8.5. By End-user; 13.8.6. By Country/Sub-region
14. Asia Pacific Liposome Drug Delivery Market Analysis and Forecast: 14.1. Introduction; 14.1.1. Key Findings; 14.2. Market Value Forecast By Liposome Structure, 2017-2031; 14.2.1. Unilamellar Liposomes; 14.2.1.1. Small; 14.2.1.2. Large; 14.2.2. Multilamellar liposomes; 14.2.3. Others; 14.3. Market Value Forecast, by Product, 2017-2031; 14.3.1. Liposomal Doxorubicin; 14.3.2. Liposomal Paclitaxel; 14.3.3. Liposomal Amphotericin B; 14.3.4. Others; 14.4. Market Value Forecast, by Technology, 2017-2031; 14.4.1. Stealth Liposome Technology; 14.4.2. Non PEGylated Liposome Technology; 14.4.3. DepoFoam Liposome Technology; 14.4.4. Lysolipid Thermally Sensitive Liposome Technology; 14.5. Market Value Forecast, by Application, 2017-2031; 14.5.1. Fungal Diseases; 14.5.2. Cancer Therapy; 14.5.3. Pain Management; 14.5.4. Viral Vaccines; 14.5.5. Photodynamic Therapy; 14.5.6. Others; 14.6. Market Value Forecast, by End-user, 2017-2031; 14.6.1. Hospitals; 14.6.2. Specialty Centers; 14.6.3. Ambulatory Surgical Centers; 14.6.4. Others; 14.7. Market Value Forecast, by Country/Sub-region, 2017-2031; 14.7.1. China; 14.7.2. Japan; 14.7.3. India; 14.7.4. Australia & New Zealand; 14.7.5. Rest of Asia Pacific; 14.8. Market Attractiveness Analysis; 14.8.1. By Liposome Structure; 14.8.2. By Product; 14.8.3. By Technology; 14.8.4. By Application; 14.8.5. By End-user; 14.8.6. By Country/Sub-region
15. Latin America Liposome Drug Delivery Market Analysis and Forecast: 15.1. Introduction; 15.1.1. Key Findings; 15.2. Market Value Forecast, by Liposome Structure, 2017-2031; 15.2.1. Unilamellar Liposomes; 15.2.1.1. Small; 15.2.1.2. Large; 15.2.2. Multilamellar liposomes; 15.2.3. Others; 15.3. Market Value Forecast, by Product, 2017-2031; 15.3.1. Liposomal Doxorubicin; 15.3.2. Liposomal Paclitaxel; 15.3.3. Liposomal Amphotericin B; 15.3.4. Others; 15.4. Market Value Forecast, by Technology, 2017-2031; 15.4.1. Stealth Liposome Technology; 15.4.2. Non PEGylated Liposome Technology; 15.4.3. DepoFoam Liposome Technology; 15.4.4. Lysolipid Thermally Sensitive Liposome Technology; 15.5. Market Value Forecast, by Application, 2017-2031; 15.5.1. Fungal Diseases; 15.5.2. Cancer Therapy; 15.5.3. Pain Management; 15.5.4. Viral Vaccines; 15.5.5. Photodynamic Therapy; 15.5.6. Others; 15.6. Market Value Forecast, by End-user, 2017-2031; 15.6.1. Hospitals; 15.6.2. Specialty Centers; 15.6.3. Ambulatory Surgical Centers; 15.6.4. Others; 15.7. Market Value Forecast, by Country/Sub-region, 2017-2031; 15.7.1. Brazil; 15.7.2. Mexico; 15.7.3. Rest of Latin America; 15.8. Market Attractiveness Analysis; 15.8.1. By Liposome Structure; 15.8.2. By Product; 15.8.3. By Technology; 15.8.4. By Application; 15.8.5. By End-user; 15.8.6. By Country/Sub-region
16. Middle East & Africa Liposome Drug Delivery Market Analysis and Forecast: 16.1. Introduction; 16.1.1. Key Findings; 16.2. Market Value Forecast, by Liposome Structure, 2017-2031; 16.2.1. Unilamellar Liposomes; 16.2.1.1. Small; 16.2.1.2. Large; 16.2.2. Multilamellar liposomes; 16.2.3. Others; 16.3. Market Value Forecast, by Product, 2017-2031; 16.3.1. Liposomal Doxorubicin; 16.3.2. Liposomal Paclitaxel; 16.3.3. Liposomal Amphotericin B; 16.3.4. Others; 16.4. Market Value Forecast, by Technology, 2017-2031; 16.4.1. Stealth Liposome Technology; 16.4.2. Non PEGylated Liposome Technology; 16.4.3. DepoFoam Liposome Technology; 16.4.4. Lysolipid Thermally Sensitive Liposome Technology; 16.5. Market Value Forecast, by Application, 2017-2031; 16.5.1. Fungal Diseases; 16.5.2. Cancer Therapy; 16.5.3. Pain Management; 16.5.4. Viral Vaccines; 16.5.5. Photodynamic Therapy; 16.5.6. Others; 16.6. Market Value Forecast, by End-user, 2017-2031; 16.6.1. Hospitals; 16.6.2. Specialty Centers; 16.6.3. Ambulatory Surgical Centers; 16.6.4. Others; 16.7. Market Value Forecast, by Country/Sub-region, 2017-2031; 16.7.1. GCC Countries; 16.7.2. South Africa; 16.7.3. Rest of Middle East & South Africa; 16.8. Market Attractiveness Analysis; 16.8.1. By Liposome Structure; 16.8.2. By Product; 16.8.3. By Technology; 16.8.4. By Application; 16.8.5. By End-user; 16.8.6. By Country/Sub-region
17. Competition Landscape: 17.1. Market Player - Competition Matrix, by tier and size of companies; 17.2. Market Share Analysis, by Company, 2021; 17.3. Company Profiles; 17.3.1. Johnson & Johnson Services, Inc.; 17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength); 17.3.1.2. Product Portfolio; 17.3.1.3. Financial Overview; 17.3.1.4. SWOT Analysis; 17.3.1.5. Strategic Overview; 17.3.2. Gilead Sciences, Inc.; 17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength); 17.3.2.2. Product Portfolio; 17.3.2.3. Financial Overview; 17.3.2.4. SWOT Analysis; 17.3.2.5. Strategic Overview; 17.3.3. Sun Pharmaceutical Industries Ltd.; 17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength); 17.3.3.2. Product Portfolio; 17.3.3.3. Financial Overview; 17.3.3.4. SWOT Analysis; 17.3.3.5. Strategic Overview; 17.3.4. Novartis AG; 17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength); 17.3.4.2. Product Portfolio; 17.3.4.3. Financial Overview; 17.3.4.4. SWOT Analysis; 17.3.4.5. Strategic Overview; 17.3.5. Teva Pharmaceutical Industries Ltd; 17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength); 17.3.5.2. Product Portfolio; 17.3.5.3. Financial Overview; 17.3.5.4. SWOT Analysis; 17.3.5.5. Strategic Overview; 17.3.6. Janssen Pharmaceuticals, Inc.; 17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength); 17.3.6.2. Product Portfolio; 17.3.6.3. Financial Overview; 17.3.6.4. SWOT Analysis; 17.3.6.5. Strategic Overview; 17.3.7. CELSION Corporation; 17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength); 17.3.7.2. Product Portfolio; 17.3.7.3. Financial Overview; 17.3.7.4. SWOT Analysis; 17.3.7.5. Strategic Overview; 17.3.8. Abbott; 17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength); 17.3.8.2. Product Portfolio; 17.3.8.3. Financial Overview; 17.3.8.4. SWOT Analysis; 17.3.8.5. Strategic Overview; 17.3.9. Ipsen Pharma; 17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength); 17.3.9.2. Product Portfolio; 17.3.9.3. Financial Overview; 17.3.9.4. SWOT Analysis; 17.3.9.5. Strategic Overview; 17.3.10. Spectrum Pharmaceuticals, Inc.; 17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength); 17.3.10.2. Product Portfolio; 17.3.10.3. Financial Overview; 17.3.10.4. SWOT Analysis; 17.3.10.5. Strategic Overview; 17.3.11. Takeda Pharmaceutical Company Limited; 17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength); 17.3.11.2. Product Portfolio; 17.3.11.3. Financial Overview; 17.3.11.4. SWOT Analysis; 17.3.11.5. Strategic Overview